Company profile for Neuraly

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Neuraly is a clinical stage biopharmaceutical company founded by scientists and physicians with a worldwide reputation in the field of neurodegenerative diseases. Our mission is to translate scientific discoveries in neurology into revolutionary new drugs that can radically change improve and prolong the lives of people suffering from the devastating consequences of diseases such as Parkinson’s disease, Alzheimer’s dise...
Neuraly is a clinical stage biopharmaceutical company founded by scientists and physicians with a worldwide reputation in the field of neurodegenerative diseases. Our mission is to translate scientific discoveries in neurology into revolutionary new drugs that can radically change improve and prolong the lives of people suffering from the devastating consequences of diseases such as Parkinson’s disease, Alzheimer’s disease and other neurodegenerative disorders.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
20271 Goldenrod Ln, Germantown, Maryland 20876, US
Telephone
Telephone
+1-301-804-0938
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

IMCAS World Congress

IMCAS World Congress

Not Confirmed

envelop Contact Supplier

IMCAS World Congress

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20230327005069/en

BUSINESSWIRE
27 Mar 2023
Neuraly points to younger patients as Parkinson's bet fails
Neuraly points to younger patients as Parkinson's bet fails

27 Mar 2023

// Annalee Armstrong FIERCE BIOTECH

https://www.fiercebiotech.com/biotech/neuraly-points-younger-patients-hope-parkinsons-bet-fails-phase-2

Annalee Armstrong FIERCE BIOTECH
27 Mar 2023

https://www.businesswire.com/news/home/20220418005572/en

BUSINESSWIRE
19 Apr 2022

https://www.businesswire.com/news/home/20210428005042/en

BUSINESSWIRE
28 Apr 2021

https://www.businesswire.com/news/home/20201110005067/en/Neuraly-Announces-Strategic-Sponsored-Research-Agreement-with-the-University-of-Pennsylvania-to-Explore-use-of-NLY01-to-Therapeutically-Target-a-Neuroinflammatory-Mechanism-of-Glaucoma

BUSINESSWIRE
10 Nov 2020

https://www.businesswire.com/news/home/20201102005054/en/Neuraly-Receives-FDA-Clearance-of-Investigational-New-Drug-Application-to-Initiate-Phase-2B-Trial-of-NLY01-for-Patients-with-Alzheimer%E2%80%99s-Disease

BUSINESSWIRE
02 Nov 2020

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty